Heartflow, Inc. Common Stock
HTFL
$49.36
-2.62%
Heartflow, Inc. is a commercial-stage medical technology company that develops software and artificial intelligence designed to provide a non-invasive solution for diagnosing and managing coronary artery disease, with three core products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis. The company operates as a single reportable segment focused on non-invasive coronary artery disease detection, generating the majority of its revenue from the United States with additional operations in Europe, positioning it as a niche AI-driven disruptor in the cardiac diagnostics space rather than a broad-based medtech platform. The current investor narrative centers on the company's August 2026 second-quarter results, which featured raised full-year guidance and strong revenue growth, triggering a sharp single-day stock move and fueling debate over whether the company can sustain its growth trajectory while narrowing persistent losses. With a market capitalization of roughly $4.15 billion, 843 employees, and a listing date of August 2025, Heartflow is an early-stage public company whose story hinges on AI-enabled diagnostic adoption, reimbursement expansion, and the path to profitability, making it an attractive but high-risk growth investment in the healthcare information services industry.…
HTFL
Heartflow, Inc. Common Stock
$49.36
Investment Opinion: Should I buy HTFL Today?
Rating: Hold. The core thesis is that Heartflow is a high-growth, AI-driven medtech disruptor with a strong balance sheet and accelerating revenue, but its premium valuation and persistent losses create an unfavorable near-term risk/reward. The analyst consensus is 'buy' with a recommendation mean of 1.6, yet the average target price of $46.00 implies a 6.7% downside from the current $49.32, suggesting the stock has run ahead of fundamental fair value.
Supporting evidence: Revenue is projected to reach $515.88 million on average, with a tight range indicating high confidence. Gross margin is an impressive 76.80%, typical of a software business, and the balance sheet is robust with a current ratio of 5.20 and debt-to-equity of 0.073. However, the company remains unprofitable with a net margin of -66.35% and negative free cash flow (price-to-cash-flow of -46.02). The valuation is rich: PS of 14.12 and EV/Sales of 19.42 are well above the 4x-8x sector average, and the PEG ratio of 2.03 suggests the growth premium is already priced in. The high analyst target of $56.00 offers 13.5% upside, but the low target of $39.00 implies 20.9% downside, reflecting significant disagreement.
Risks and conditions: The biggest risks are a deceleration in revenue growth, reimbursement pressures, and a delay in achieving profitability. This Hold would upgrade to Buy if the stock pulls back to the $40-$42 range (near the analyst average target) or if the company demonstrates clear progress toward positive free cash flow. It would downgrade to Sell if revenue growth falls below 20% year-over-year or if gross margin declines below 70%. Relative to its history and peers, the stock appears overvalued on near-term metrics, but the premium may be justified if growth accelerates and profitability inflects.
Sign up to view all
HTFL 12-Month Price Forecast
Heartflow presents a compelling long-term growth story as an AI-driven disruptor in cardiac diagnostics, but the current valuation already prices in significant execution success. The stock's 98.63% six-month gain and premium PS multiple leave little room for error, and the fact that it trades above the average analyst target suggests near-term upside is limited. The company's strong gross margins and fortress balance sheet are offset by persistent losses and negative free cash flow, making the path to profitability the key swing factor. I would upgrade to bullish if the stock pulls back to the $40-$42 range or if the company demonstrates clear progress toward positive free cash flow. I would downgrade to bearish if revenue growth decelerates below 20% or if reimbursement headwinds emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Heartflow, Inc. Common Stock's 12-month outlook, with a consensus price target around $46.00 and implied upside of -6.8% versus the current price.
Average Target
$46.00
0 analysts
Implied Upside
-6.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$39 - $56
Analyst target range
Heartflow is covered by 9 analysts, with a consensus recommendation of "buy" and a recommendation mean of 1.6 on a scale where 1 is a strong buy and 5 is a strong sell, indicating a bullish tilt among the covering cohort. The average target price is $46.00, which implies a downside of approximately -6.7% from the current price of $49.32, meaning the stock is trading above the consensus target despite the buy rating. This unusual setup suggests that analysts have not yet fully updated their targets following the sharp August 2026 rally, or that the market has run ahead of fundamental expectations, creating a potential near-term disconnect between price and consensus fair value. The target range spans from a low of $39.00 to a high of $56.00, a spread of $17.00, or approximately 43.6% of the low target, which signals meaningful disagreement among analysts about the company's trajectory. The high target of $56.00 implies roughly 13.5% upside from the current price and likely assumes continued revenue acceleration, successful new product adoption, and progress toward profitability that justifies multiple expansion. The low target of $39.00 implies approximately 20.9% downside and likely prices in risks such as slower-than-expected adoption, reimbursement headwinds, margin compression, or competitive pressures in the coronary diagnostics market. The estimated EPS average of $0.61, with a tight range of $0.598 to $0.631, suggests analysts have relatively high confidence in the near-term earnings trajectory, which contrasts with the wide price target spread and implies the uncertainty is more about valuation multiples than operational performance. The consensus buy rating combined with a price above the average target creates a cautious near-term signal, and investors should watch for target revisions in the coming weeks to see whether analysts raise their estimates to align with the stock's new trading range.
Drowning in data?
Find the real signal!
Bulls vs Bears: HTFL Investment Factors
The bull case rests on Heartflow's exceptional revenue growth trajectory, software-like gross margins of 76.80%, a fortress balance sheet with a current ratio of 5.20 and debt-to-equity of 0.073, and a strong analyst consensus with a high target of $56.00. The bear case centers on an extreme valuation (PS of 14.12, EV/Sales of 19.42), persistent GAAP losses with a -66.35% net margin, a current price that exceeds the average analyst target of $46.00, and severe historical volatility with a -48.66% max drawdown. Currently, the bear evidence carries slightly more weight for near-term investors because the stock trades above consensus fair value and has shown momentum deceleration, while the bull case is more compelling for long-term investors who believe in the durability of the growth story. The single most important tension is whether the company can sustain its accelerating revenue growth while simultaneously narrowing losses to justify its premium multiple; if revenue growth decelerates or reimbursement pressures emerge, the high PS ratio could compress sharply, but if profitability inflects, the stock could re-rate higher.
Bullish
- Explosive revenue growth trajectory: Analyst revenue estimates average $515.88 million, with a tight range of $506.21M to $527.43M, indicating high confidence in continued top-line expansion. The August 2026 Q2 results featured raised full-year guidance, explicitly signaling accelerating growth that drove a single-day stock jump from $31.01 to $42.08.
- Software-like gross margins: Gross margin of 76.80% is exceptional for a medtech company and reflects the asset-light, AI-driven nature of Heartflow's diagnostic platform. This high gross margin provides substantial operating leverage potential as revenue scales, since the path to profitability depends mainly on absorbing fixed opex rather than improving unit economics.
- Fortress balance sheet with minimal debt: Current ratio of 5.20 and debt-to-equity of just 0.073 indicate ample liquidity and virtually no leverage risk. This financial flexibility allows the company to fund its commercial expansion and R&D without near-term solvency concerns, even while free cash flow remains negative.
- Strong analyst consensus and high target: 9 analysts rate the stock a 'buy' with a recommendation mean of 1.6, and the high target of $56.00 implies 13.5% upside from the current $49.32. The tight EPS estimate range ($0.598 to $0.631) suggests analysts have high confidence in the near-term earnings trajectory, contrasting with the wider price target spread.
Bearish
- Extreme valuation leaves no margin for error: Price-to-sales of 14.12 and EV/Sales of 19.42 are far above the 4x-8x range typical for mature healthcare information services companies. The PEG ratio of 2.03 further indicates the stock is not cheap even after adjusting for growth, meaning any deceleration could trigger a severe multiple compression.
- Persistent GAAP losses and cash burn: Net margin is -66.35%, operating margin is -36.39%, and EPS is -$0.047, with negative free cash flow reflected in the -46.02 price-to-cash-flow ratio. The company remains dependent on its cash reserves to fund operations, and the transition to positive free cash flow is a critical but unproven milestone.
- Price exceeds analyst average target: The current price of $49.32 is 6.7% above the consensus average target of $46.00, an unusual setup that suggests either analysts have not yet updated their models post-Q2 or the market has run ahead of fundamentals. This disconnect creates a near-term headwind if targets are not revised upward.
- Severe historical volatility and drawdown risk: The maximum drawdown of -48.66% highlights the stock's extreme price swings, and the 52-week low of $20.13 is 59.2% below the current price. With a limited public trading history since August 2025, there is little historical support to anchor valuation during a selloff.
HTFL Technical Analysis
Heartflow is in a powerful, sustained uptrend, with the current price of $49.32 representing a 36.28% gain over the past year and a 98.63% gain over the past six months, though the stock only listed in August 2025 so the 1-year figure reflects a partial trading history. The stock is trading at approximately 94.5% of its 52-week range, calculated as ($49.32 - $20.13) / ($52.221 - $20.13), placing it just below its 52-week high of $52.221 and far above its 52-week low of $20.13. This positioning near the top of the range signals strong momentum but also raises the risk of overextension, particularly after a move of this magnitude in a relatively short period. Recent momentum shows a sharp deceleration, with the 1-month change at -1.36% contrasting with the 3-month change of +76.36% and the year-to-date gain of +70.25%. This divergence suggests the stock is digesting its massive August 2026 rally, which was catalyzed by raised guidance and strong Q2 results, and the negative 1-month relative strength of -1.95% versus SPY indicates the stock is underperforming the market on a short-term basis after its run. The 3-month relative strength of +73.02% and 6-month relative strength of +81.28% confirm that the medium-term trend remains overwhelmingly positive, so the recent pullback appears to be a consolidation phase rather than a trend reversal. Key technical support sits at the 52-week low of $20.13, with a more immediate support zone likely around the $45-$47 area where the stock has found buyers in September 2026, while resistance is defined by the 52-week high of $52.221. A breakout above $52.221 would signal renewed momentum and likely target new all-time highs, whereas a breakdown below the $45 support area could trigger a deeper mean-reversion move toward the $40 level. The maximum drawdown of -48.66% highlights the stock's severe historical volatility, and while beta is not provided, the magnitude of these price swings suggests a high-beta profile that warrants careful position sizing and risk management.
Beta
—
—
Max Drawdown
-48.7%
Largest decline past year
52-Week Range
$20-$54
Price range past year
Annual Return
+41.1%
Cumulative gain past year
| Period | HTFL Return | S&P 500 |
|---|---|---|
| 1m | +0.9% | +0.9% |
| 3m | +78.1% | +3.4% |
| 6m | +83.2% | +14.4% |
| 1y | +41.1% | +16.2% |
| ytd | +70.4% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HTFL Fundamental Analysis
Heartflow's revenue trajectory is clearly growth-oriented, with analyst estimates projecting average revenue of approximately $515.88 million, within a range of $506.21 million to $527.43 million, reflecting the company's expanding commercial footprint in AI-driven coronary diagnostics. The August 2026 news headline explicitly cites "raised guidance and strong Q2 results" that signal "accelerating growth," indicating that the most recent quarter likely exceeded prior expectations and that management has increased its forward outlook. However, detailed quarterly financials, income statements, and revenue segment data are not available in the provided dataset, so the precise multi-quarter growth rate and the breakdown of which products are driving growth cannot be quantified. The investment case rests on whether this acceleration is durable, particularly as the company scales its FFRCT, Roadmap, and Plaque Analysis products across U.S. and European markets. Profitability remains a work in progress, with a net margin of -66.35%, an operating margin of -36.39%, and a negative EPS of -$0.047, indicating the company is still unprofitable on a GAAP basis. The gross margin of 76.80% is strong and typical of a software-driven medtech business, suggesting that the core unit economics are attractive and that the path to profitability depends on scaling revenue to absorb operating expenses rather than fixing gross-level economics. The gap between the 76.80% gross margin and the -36.39% operating margin implies substantial sales, marketing, and R&D spending, which is expected for a commercial-stage company investing in market adoption. The balance sheet is a clear strength, with a current ratio of 5.20 and a debt-to-equity ratio of just 0.073, indicating ample liquidity and minimal leverage. However, the company is not generating positive free cash flow, as evidenced by the negative price-to-cash-flow ratio of -46.02 and a negative ROE of -38.85%, meaning it currently depends on its cash reserves or external financing to fund operations. The low debt-to-equity ratio of 0.073 and high current ratio of 5.20 suggest financial risk is low in the near term, but the negative ROA of -18.06% and negative ROE of -38.85% highlight that capital is not yet being deployed profitably, making the transition to positive free cash flow a critical milestone for the investment thesis.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HTFL Overvalued?
Because Heartflow's trailing net income is negative, with a trailing PE of -21.28 and a negative EPS of -$0.047, the PE ratio is not meaningful for valuation; the price-to-sales ratio of 14.12 is the appropriate primary metric, and the EV/Sales ratio of 19.42 provides a corroborating view. The forward PE of -191.68 is also negative, reflecting that analysts expect the company to remain unprofitable on a GAAP basis in the near term, though the estimated EPS average of $0.61 suggests a swing toward profitability on a non-GAAP or adjusted basis. The gap between the negative trailing PE and the negative forward PE implies the market is pricing in a significant improvement in earnings, but the current valuation is being driven by revenue growth expectations rather than near-term earnings power. Comparing Heartflow's PS ratio of 14.12 and EV/Sales of 19.42 to the broader healthcare information services sector, where mature companies often trade at 4x-8x sales, Heartflow commands a substantial premium that reflects its high growth rate, AI differentiation, and 76.80% gross margin. The PB ratio of 8.27 is also elevated, consistent with a high-growth, asset-light software company, while the PEG ratio of 2.03 suggests the stock is not cheap even after adjusting for growth. The premium is arguably justified by the company's 98.63% six-month price appreciation and accelerating revenue trajectory, but it leaves little margin for error if growth decelerates or reimbursement pressures emerge. Historical ratio data is not available in the provided dataset, so the current valuation cannot be compared to the stock's own historical PE or PS band. Given the stock's listing date of August 2025, it has a limited public trading history, which means the current PS of 14.12 and EV/Sales of 19.42 may represent the higher end of its historical range following the August 2026 rally, when the stock jumped from around $31 to over $42 in a single day. Without historical context, investors should treat the current multiple as a growth premium that requires sustained execution to justify.
PE
-21.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-26.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant despite a strong balance sheet. The company is unprofitable with a net margin of -66.35% and operating margin of -36.39%, and it is not generating positive free cash flow (price-to-cash-flow of -46.02). With a negative ROE of -38.85% and ROA of -18.06%, capital is not yet being deployed profitably, and the company relies on its cash reserves (current ratio of 5.20) to fund operations. The low debt-to-equity of 0.073 mitigates solvency risk, but the path to profitability depends entirely on scaling revenue to absorb substantial sales, marketing, and R&D expenses. Any slowdown in revenue growth could force additional equity dilution or delay the breakeven timeline, pressuring the stock.
Market and competitive risks are elevated given the premium valuation and niche positioning. The stock trades at a PS of 14.12 and EV/Sales of 19.42, well above the 4x-8x range for mature healthcare information services peers, leaving little room for error. As a single-segment company focused on non-invasive coronary artery disease detection, Heartflow faces competition from established diagnostic modalities and potential new entrants. Reimbursement expansion is critical; any adverse changes in Medicare or private payer coverage could severely impact adoption. The stock's high beta (implied by a -48.66% max drawdown and 98.63% six-month gain) makes it vulnerable to sector rotation and macro risk, especially if interest rates remain elevated and compress growth stock multiples. Recent news highlights the stock's sharp reaction to Q2 results, but also underscores its sensitivity to guidance changes.
Worst-case scenario: A combination of slower-than-expected revenue growth, reimbursement headwinds, and a delay in profitability could trigger a severe de-rating. If the stock were to retest its 52-week low of $20.13, that would represent a 59.2% decline from the current price of $49.32. The analyst low target of $39.00 implies a 20.9% downside, but in a more bearish scenario where the PS multiple compresses to 8x forward sales (still a premium to peers), the stock could fall toward the $25-$30 range. Given the limited trading history and high volatility, investors should be prepared for drawdowns exceeding 50% in adverse conditions.
FAQ
The key risks for HTFL are ranked as follows: 1) Financial risk: The company is unprofitable with a net margin of -66.35% and negative free cash flow (price-to-cash-flow of -46.02), meaning it relies on cash reserves to fund operations. 2) Valuation risk: The stock trades at a PS of 14.12, leaving little room for error; any growth deceleration could trigger a sharp multiple compression. 3) Competitive and reimbursement risk: As a single-segment company focused on coronary diagnostics, it faces competition from established modalities and potential new AI entrants; adverse reimbursement changes could severely impact adoption. 4) Volatility risk: The stock has a maximum drawdown of -48.66% and a 52-week low of $20.13, which is 59.2% below the current price, indicating extreme price swings. These risks are heightened by the company's limited public history and dependence on continued execution.
The 12-month forecast for HTFL includes three scenarios. The bull case (25% probability) targets $56-$65, assuming revenue growth exceeds 30% and profitability inflects, driven by reimbursement expansion and new product adoption. The base case (55% probability) targets $44-$50, assuming steady 20-25% revenue growth and gradual margin improvement, with the stock consolidating around the analyst average target of $46. The bear case (20% probability) targets $30-$39, triggered by revenue growth slowing below 15%, reimbursement headwinds, or a dilutive financing. The most likely scenario is the base case, with the key assumption that revenue grows in line with analyst estimates of $515.88 million and the company makes progress toward breakeven without major setbacks.
HTFL appears overvalued on traditional metrics. Its price-to-sales ratio of 14.12 and EV/Sales of 19.42 are significantly above the 4x-8x range typical for mature healthcare information services companies. The PEG ratio of 2.03 also indicates a premium relative to growth. Since the company is unprofitable, the PE ratio is negative and not meaningful. The market is pricing in substantial future growth and eventual profitability, as evidenced by the forward PE of -191.68, which implies analysts expect a swing to positive earnings on an adjusted basis (estimated EPS of $0.61). Compared to its own history, the stock has limited trading history since its August 2025 IPO, but the current PS multiple is likely at the higher end of its range following the August 2026 rally. The valuation implies the market expects revenue to continue growing at over 20% annually and margins to expand significantly.
From a risk/reward perspective, HTFL is a speculative buy for long-term investors but a hold for near-term traders. The stock has strong revenue growth (analyst estimates of $515.88 million) and a high gross margin of 76.80%, but it trades at a premium valuation (PS of 14.12) and is unprofitable with a net margin of -66.35%. The analyst consensus is 'buy' with a high target of $56.00, implying 13.5% upside, but the average target of $46.00 suggests the stock is currently overvalued by 6.7%. The biggest downside risk is a retest of the 52-week low of $20.13, which would represent a 59.2% loss. Therefore, it is a good buy only for investors who can tolerate high volatility and believe in the company's ability to achieve profitability within 2-3 years.
HTFL is more suitable for long-term investment than short-term trading. The company is in a high-growth phase, with revenue expected to reach $515.88 million, but it is not yet profitable and does not pay a dividend. The stock's beta is not provided, but its maximum drawdown of -48.66% and 98.63% six-month gain indicate high volatility, making it risky for short-term traders. Earnings visibility is limited due to its early-stage public status and dependence on reimbursement decisions. A suggested minimum holding period is 3-5 years to allow for the commercialization ramp and potential profitability inflection. Short-term traders might find opportunities around earnings announcements, but the risk of sharp reversals is significant.
